Otsuka Rescues Fallen Unicorn Proteus Digital
Bankrupt US Venture To Support Digital Push
Japanese firm picks up struggling US venture for a fraction of its one-time value as it continues strategic push into the digital health space.
You may also be interested in...
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.